Methodology for labeling proteins and peptides with lead-212 (212Pb)

Nuclear Medicine and Biology

Volumn 40, Issue 5, 2013, Pages 592-599

  Baidoo, Kwamena E ^a   Milenic, Diane E ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alpha targeted therapy; Cancer therapy; Lead 212; Radioimmunotherapy; Trastuzumab

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZA 1,4,7,10,TETRA (2 CARBAMONYLMETHYL)CYCLODODECANE; ANTIBODY CONJUGATE; HYDROCHLORIC ACID; LEAD 212; MONOCLONAL ANTIBODY; NITRIC ACID; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE; RADIUM 224; TETRAXETAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; DILUTION; ELUTION; EVAPORATION; EXTRACTION; FEASIBILITY STUDY; ISOTOPE LABELING; METHODOLOGY; RADIOACTIVITY; RADIOCHEMISTRY; THIN LAYER CHROMATOGRAPHY;

ISOTOPE LABELING; LEAD RADIOISOTOPES; PEPTIDES; PROTEINS;

EID: 84878174664     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.01.010     Document Type: Article

References (42)

1. Dadachova E., Casadevall A. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Expert Opin Drug Deliv 2005, 2:1075-1084.
2. Aarts F., Bleichrodt R.P., Oyen W.J., Boerman O.C. Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother Radiopharm 2008, 23:92-107.
3. Govindan S.V., Goldenberg D.M. New antibody conjugates in cancer therapy. Sci World J 2010, 10:2070-2089.
4. Steiner M., Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 2011, 17:6406-6416.
5. Milenic D.E. Antibody engineering - optimizing the delivery vehicle. Monoclonal antibody and peptide target radiotherapy of malignancies 2010, 1-38. John Wiley and Sons, Hoboken, NJ. R.M. Reilly (Ed.).
6. Ricart A.D., Tolcher A.W. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 2007, 4:245-255.
7. Carter P.J., Senter P.D. Antibody-drug conjugates for cancer therapy. Cancer J 2008, 14:154-169.
8. Milenic D.E., Brady E.D., Brechbiel M.W. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004, 3:488-499.
9. Milenic D.E. Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Curr Pharm Des 2002, 8:1749-1764.
10. Wester H.J., Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size?. J Nucl Med 2005, 46:1940-1945.
11. Boswell C.A., Brechbiel M.W. Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. J Nucl Med 2005, 46:1946-1947.
12. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23:1137-1146.
13. O'Donoghue J.A., Bardiès M., Wheldon T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995, 36:1902-1909.
14. Azzam E.I., de Toledo S.M., Little J.B. Stress signaling from irradiated to non-irradiated cells. Curr Cancer Drug Targets 2004, 4:53-64.
15. Prise K.M., Folkard M., Michael B.D. Bystander responses induced by low LET radiation. Oncogene 2003, 22:7043-7049.
16. 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur J Nucl Med Mol Imaging 2005, 32:274-285.
17. 213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 2007, 67:1950-1958.
18. 212Pb-Radioimmunotherapy induces G2 cell cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 2012, 11:639-648.
19. Vallon M., Seidl C., Blechert B., Li Z., Gilbertz K.P., Baumgart A., et al. Enhanced efficacy of combined (213)Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest. Eur J Nucl Med Mol Imaging 2012, 39:1886-1897.
20. 212Pb-radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad5. Int J Radiat Oncol Biol Phys 2013, 85:1119-1126.
21. Andersson H., Cederkrantz E., Back T., Divgi C., Elgqvist J., Himmelman J., et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2-a phase I study. J Nucl Med 2009, 50:1153-1160.
22. Rotmensch J., Atcher R.W., Hines J., Grdina D., Schwartz J.S., Toohill M., et al. The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma. Am J Obstet Gynecol 1989, 160:789-797.
23. 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional α-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001, 61:2804-2808.
24. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999, 40:1935-1946.
25. Milenic D.E., Garmestani K., Brady E.D., Albert P.S., Ma D., Abdulla A., et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004, 10:7834-7841.
26. Milenic D., Garmestani K., Dadachova E., Chappell L., Albert P., Hill D., et al. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm 2004, 19:135-147.
27. Yong K., Brechbiel M.W. Towards translation of 212Pb as a clinical therapeutic; getting the lead in!. Dalton Trans 2011, 40:6068-6076.
28. Kim Y-S, Brechbiel MW. An overview of targeted alpha therapy. Tumor Biol. 2012; 33:573-590.
29. 2. Radiochim Acta 1993, 60:1-10.
30. Su F.M., Beaumier P., Axworthy D., Atcher R., Fritzberg A. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Nucl Med Biol 2005, 32:741-747.
31. Horak E., Hartmann F., Garmestani K., Wu C., Brechbiel M., Gansow O.A., et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 1997, 38:1944-1950.
32. 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005, 20:557-568.
33. Milenic D.E., Garmestani K., Brady E.D., Albert P.S., Abdulla A., Flynn J., et al. Potentiation of high LET radiation by gemcitabine: targeting of HER2 with trastuzumab for the treatment of disseminated peritoneal disease. Clin Cancer Res 2007, 13:1926-1935.
34. Milenic D.E., Garmestani K., Brady E.D., Albert P.S., Wong K.J., Flynn J., et al. Multimodality therapy: potentiation of High-LET radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 2008, 14:5108-5115.
35. Milenic D.E., Brady E.D., Garmestani K., Albert P.S., Abdulla A., Brechbiel M.W. Improved efficacy of α-particle targeted radiation therapy: dual targeting of HER2 and TAG-72. Cancer 2010, 116(S4):1059-1066.
36. http://clinicaltrials.gov/show/NCT01384253.
37. Chappell L.L., Dadachova E., Milenic D.E., Garmestani K., Wu C., Brechbiel M.W. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol 2000, 27:93-100.
38. Ruble G., Wu C., Squire R.A., Gansow O.A., Strand M. The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int J Radiat Oncol Biol Phys 1996, 34:609-616.
39. McMurry T.J., Brechbiel M.W., Kumar K., Gansow O.A. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjug Chem 1992, 3:108-117.
40. Cuenot F., Meyer M., Espinosa E., Bucaille A., Burgat R., Guilard R., et al. New insights into the complexation of lead(II) by 1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (DOTAM): structural, thermodynamic, and kinetic studies. Eur J Inorg Chem 2008, 267-283.
41. Dadachova E., Chappell L.L., Brechbiel M.W. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999, 26:977-982.
42. Howell R.W., Azure M.T., Narra V.R., Rao D.V. Relative biological effectiveness of alpha-particle emitters in vivo at low doses. Radiat Res 1994, 137:352-360.